LENALIDOMIDE DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Size and Trends

The lenalidomide drug market is estimated to be valued at USD 13.21 Bn in 2024 and is expected to reach USD 20.45 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

To learn more about this report, request a free sample copy

The lenalidomide drug market is expected to witness a positive growth trend over the forecast period. Key factors such as the rising prevalence of cancer indication such as multiple myeloma across worldwide populations   and increased approval of the drug to treat other cancer indications will drive the demand. Furthermore, ongoing research and development activities to develop newer formulations with improved efficacy and novel drug delivery systems will aid the market expansion. However, patent expiry of the drug and subsequent market entry of generic versions can hinder the growth of the market to some extent in coming years.

Improving Outcomes for Multiple Myeloma Patients

Lenalidomide has established itself as a front-line standard of care for multiple myeloma patients. Clinical trials have demonstrated significantly higher response rates compared to previous therapies alone. Combining lenalidomide with dexamethasone gives patients a durable remission and delays disease progression. Doctors now have compelling evidence that this regimen extends survival as well. Lenalidomide not only helps put the disease into deep remission but also keeps patients in remission longer. As oncologists strive to turn multiple myeloma into a chronic condition managed with long-term therapy, lenalidomide plays a central role in this treatment paradigm shift. Its ability to deliver superior outcomes makes lenalidomide a cornerstone of current multiple myeloma treatment plans.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

The lenalidomide drug market is witnessing significant growth in the emerging markets of Asia Pacific and Latin America regions. These regions have a very large patient population who can benefit from lenalidomide treatment of blood cancer indications like multiple myeloma. Some of the key factors driving the increased adoption of lenalidomide in these regions include growing awareness about effective treatment options, increasing healthcare access and spending, and reducing costs of novel therapies. Many countries in Asia Pacific and Latin America continue to report rising incidence rates of multiple myeloma and other blood cancers associated with improving life expectancy and lifestyle changes. This is generating high demand for sophisticated treatments like lenalidomide.

To learn more about this report, request a free sample copy

The patent expiry of branded drugs is posing significant challenges for the growth of the lenalidomide drug market. Lenalidomide, which is a drug used mainly in the treatment of multiple myeloma and mantle cell lymphoma, has faced increasing competition from generic drug manufacturers after its patent expired in the U.S. in 2022.

Market Opportunities – Exploring Combination Drug Therapies:

Exploring combination therapies and testing lenalidomide in other hematological cancers could significantly expand the eligible patient pool. Pursuing pediatric indications may also unlock new growth. Extending or strengthening patents could help stave off generics. Developing new formulations or delivery methods may enhance safety and patient adherence, helping maintain competitive edge even post-patent expiry.

To learn more about this report, request a free sample copy

The application segment includes multiple myeloma (MM), transfusion-dependent anemia, mantle cell lymphoma (MCL), and others. The multiple myeloma segment is estimated to hold 40.5% share of the market in 2024, since it is an aggressive and difficult-to-treat blood cancer. Multiple myeloma stems from plasma cells which are white blood cells that help fight infection. When these cells become cancerous they multiply uncontrollably which can cause excessive crowding in the bone marrow, weakening of bones, poor immune function and other issues. While not as common as other cancers, it carries high morbidity due to complications like bone fractures from weakened bones or kidney failure from damaged nephrons. Lenalidomide has proven efficacy as a frontline treatment option either alone or in combination with dexamethasone, providing durable remission periods or improved overall survival rates. This significantly helps manage the health impacts of multiple myeloma, driving its large market share among the application segments.

Insights, By Strength: Price Sensitivity Driving 25 mg Strength segment growth

The strength segment includes 10 mg, 20 mg, 25 mg, and others. The 25 mg subsegment is expected to have 35.8% of the market share in 2024, owing to its price sensitivity among patients and doctors. The 25 mg strength allows flexibility in dosing which is important for safe and effective treatment. Doctors often prefer to start patients on the 25 mg pill since it provides an optimal balance of managing side effects and response to treatment. Being the mid-range option among the available strengths, it offers a good balance of efficacy and affordability for many patients and healthcare systems. The ability to adjust dosage incrementally up or down makes it a preferred initial prescription over the 10 mg or 20 mg options in many cases.

Insights, By Distribution Channel: Safety Concerns Driving Distribution through Hospital Pharmacies

The distribution channel segment includes hospital pharmacies, online pharmacies, and retail pharmacies. The Hospital Pharmacies segment accounts for the highest share of the market and is anticipated to hold 35.8% of the market share in 2024. The use of lenalidomide requires close patient monitoring due to concerns over specific safety issues like teratogenicity and thrombosis. Pregnancy should always be avoided while on lenalidomide treatment due to the high risk of severe birth defects. Additionally, there is an increased risk of developing blood clots when taking lenalidomide that requires surveillance. Hospital pharmacies have the infrastructure, trained staff, and established protocols to dispense such specialty drugs and monitor for early signs of adverse reactions. This allows for timely intervention or adjustment of treatment as needed. The safety oversight provided through hospital dispensing puts patients at ease and earns physician preference over other channels.

Regional Insights

To learn more about this report, request a free sample copy

North America has established itself as the dominant region in the global lenalidomide drug market and is projected to hold 43.8% of the market share in 2024 with the U.S. being the single largest pharmaceutical market. The strong presence of key manufacturers like Bristol-Myers Squibb, which holds the patent for Lenalidomide, has enabled robust supply chain and distribution channels in the region. Additionally, North America is among the highly developed markets with the highest per capita healthcare expenditure and strong reimbursement structure. This encourages higher patient affordability and adoption of premium drugs like Lenalidomide.

The pharmaceutical industry in the U.S. also invests heavily in R&D and clinical trials. This has helped establish North America as a strategic hub for new drug development and innovation. Lenalidomide being a breakthrough drug for lymphoma and myeloma treatment has benefited significantly. With a large patient pool and rapidly aging population, the region provides a steady market for drugs targeting such life-threatening diseases.

The lenalidomide drug market in the Asia Pacific region is anticipated to develop at the highest CAGR over the forecasted period. In Asia Pacific, the Multiple Myeloma (MM) subsegment dominates the application segment for lenalidomide drug market. Regulatory approvals, launch of new products and increasing prevalence of cancer are some of the major factors driving the market development in this region. For instance, in March 2023, Aurobindo Pharma Limited, a pharmaceutical company, announced that its wholly owned subsidiary company, Eugia Pharma Specialities Limited, has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market Lenalidomide Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg, which is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Revlimid Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg, of Bristol-Myers Squibb Company.

Market Report Scope

Key Developments

• In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and NATCO Pharma Limited, a pharmaceutical company, announced the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules) in the U.S., including 2.5 mg and 20 mg strengths
• In September 2022, Lotus Pharmaceutical, a multinational pharmaceutical company, announced the launch of lenalidomide Capsules (generic version of Revlimid) in the U.S. in strengths of 5mg, 10mg, 15mg, and 25mg
• In September 2022, Zydus Lifesciences Limited, a pharmaceutical company, announced that it had received the U.S. Food and Drug Administration (FDA) approval to market Lenalidomide Capsules, USP 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. The company has gained final clearances for 5 mg, 10 mg, 15 mg, and 25 mg strengths, as well as preliminary approvals for 2.5 mg and 20 mg strength.
• In September 2022, Cipla Limited, an India-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted final approval for its Abbreviated New Drug Application (ANDA) for lenalidomide Capsule 5 mg, 10 mg, 15 mg, and 25 mg

*Definition: The Lenalidomide Drug Market includes the sales of lenalidomide, a prescription drug used to treat multiple myeloma and myelodysplastic syndromes. Lenalidomide is an immunomodulatory drug that works by enhancing the immune system and inhibiting angiogenesis. It is used in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Lenalidomide is also used on its own or in combination with erythropoietin.

Market Segmentation

• Application Insights (Revenue, USD  Bn, 2019 - 2031)
  • Multiple myeloma (MM)
  • Transfusion-dependent anemia
  • Mantle cell lymphoma (MCL)
  • Others
•  Strength Insights (Revenue, USD  Bn, 2019 - 2031)
  • 10 mg
  • 20 mg
  • 25 mg
  • Others
•  Distribution Channel Insights (Revenue, USD  Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
• Regional Insights (Revenue, USD  Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
    • Latin America
  • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Dr. Reddy’s Laboratories Ltd. 
  • Cipla Inc. 
  • Apotex Inc.
  • Viatris Inc. 
  • Sun Pharmaceutical Industries Ltd.  
  • Lotus
  • NATCO Pharma Limited
  • Sandoz Group AG
  • Aurobindo Pharma
  • Zydus Group
  • Intas Pharmaceuticals Ltd.